ROIV Roivant Sciences Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1635088 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY102.1%
TTM net income YoY7.9%
TTM EPS YoY-5.5%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,358.1%
Net margin-838.2%
FCF margin-81.2%
EBITDA margin-1,352.0%
Returns
ROE-8.2%
ROA-6.9%
ROIC (approx.)-16.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets7.6%
Debt / equity0.00x
Current ratio15.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue-7.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-03-31 | FY20242025-03-31 | FY20232024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M |
| R&D expense | $681.81M | $550.41M | $439.91M | $454.06M | $483.04M |
| SG&A expense | $610.47M | $591.41M | $416.13M | $383.45M | $775.03M |
| Operating income | -$515.07M | -$1.00B | $4.50B | -$906.76M | -$1.35B |
| Interest expense | — | — | $34.78M | $27.97M | $7.04M |
| Pretax income | -$264.58M | -$681.59M | $4.57B | -$884.99M | -$923.75M |
| Income tax | $133.33M | $48.17M | $21.50M | $4.08M | $369,000 |
| Net income | -$299.77M | -$171.98M | $4.35B | -$1.01B | -$845.26M |
| EBITDA | -$511.72M | -$989.22M | $4.52B | -$887.91M | -$1.35B |
| EPS (basic) | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 |
| EPS (diluted) | -0.54 | -0.24 | 5.23 | -1.42 | -1.26 |
| Weighted avg. shares (diluted) | 693.86M | 725.40M | 831.05M | 712.79M | 669.75M |
| Balance sheet | |||||
| Cash & equivalents | $1.42B | $2.72B | $6.49B | $1.69B | $2.07B |
| Short-term investments | $2.87B | $2.17B | $0 | — | — |
| Receivables | — | — | $3.99M | $30.38M | $3.88M |
| Inventory | — | — | $35.25M | $2.76M | $0 |
| Current assets | $5.17B | $5.00B | $6.73B | $1.80B | $2.15B |
| PP&E, net | $11.99M | $12.06M | $15.32M | $39.09M | $25.91M |
| Intangibles | — | — | $137.84M | $144.88M | $0 |
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B |
| Current liabilities | $281.24M | $149.41M | $266.76M | $272.45M | $184.37M |
| Short-term debt | — | — | $12.00M | $40.72M | $0 |
| Long-term debt | — | — | $430.59M | $375.51M | $210.03M |
| Total debt | — | — | $442.59M | $416.24M | $210.03M |
| Total liabilities | $416.27M | $249.74M | $773.95M | $782.02M | $523.70M |
| Shareholders' equity | $4.53B | $4.69B | $5.97B | $1.16B | $1.66B |
| Net debt | — | — | -$6.05B | -$1.28B | -$1.86B |
| Shares outstanding | 720.35M | 695.94M | 806.68M | 760.14M | 694.98M |
| Cash flow statement | |||||
| Operating cash flow | -$750.35M | -$839.45M | -$765.27M | -$843.39M | -$677.73M |
| Capital expenditure | $8.21M | $4.60M | $1.38M | $12.69M | $17.44M |
| Free cash flow | -$758.56M | -$844.05M | -$766.65M | -$856.08M | -$695.16M |
| Investing cash flow | -$682.33M | -$1.77B | $5.20B | -$44.27M | $303.30M |
| Financing cash flow | $134.24M | -$1.22B | $419.36M | $499.46M | $306.79M |
| Depreciation & amortization | $3.35M | $14.07M | $22.04M | $18.86M | $5.93M |
| Stock-based compensation | $346.17M | $289.03M | $199.63M | $217.78M | $564.96M |
| Share buybacks | — | $1.29B | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.